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Abstract
Background and Aims: Conventional thiopurine [azathioprine and mercaptopurine] treatment 
during pregnancy in patients with inflammatory bowel disease [IBD] is considered to be safe; 
however data on the safety and teratogenicity of the non-conventional thiopurine tioguanine 
[TG] in pregnant IBD patients are lacking. We aim to describe the safety and teratogenicity of TG 
treatment during pregnancy in IBD patients.
Methods: This was a retrospective, multicentre descriptive case series of female IBD patients using 
TG during pregnancy. Data on disease and medication history, pregnancy complications, pregnancy 
outcome, mode of delivery, preterm birth, birthweight, congenital abnormalities, laboratory signs 
of myelosuppression or hepatotoxicity, and 6-thioguaninenucleotide [6-TGN] concentrations in 
mother and neonate were collected.
Results: In all, 13 patients [77% Crohn’s disease, 23% ulcerative colitis] used TG [median 
dose 18 g/day] during pregnancy; 19 pregnancies, including 1 twin pregnancy, were included. 
Spontaneous abortion occurred in three pregnancies. In 7 of the 16 ongoing pregnancies a 
caesarean section was performed. One neonate had a mild congenital abnormality [distal shaft 
hypospadias]. In the singleton pregnancies, the median birthweight was 3410 g at a median 
of gestational age of 39 weeks. No preterm birth [< 37 weeks] or low birthweight [< 2500 g] 
was observed in the singleton newborns. In the twin pregnancy an induction of labour was 
performed at 35 + 1 weeks of gestation because of pre-eclampsia. Both neonates had a low 
birthweight.






Conclusions: This relatively small case series supports safe use of TG in pregnant IBD patients. Still, 
consideration should be given to the indication and continuation of TG during pregnancy.
Key Words:  Pregnancy; tioguanine; inflammatory bowel disease
1. Introduction
Inflammatory bowel disease [IBD] has a peak prevalence during 
the reproductive years. An exacerbation in disease activity during 
conception and pregnancy is associated with low birthweight and 
premature birth.1,2,3 Consequently, it is of great importance that the 
safety profile of maintenance medication prescribed during preg-
nancy is balanced against the potential risk of disease relapse for 
both mother and fetus.
Conventional immune-modulating thiopurines, azathioprine 
[AZA] and mercaptopurine [MP], have proven to be effective in 
IBD in both inducing and maintaining clinical remission.4,5 The 
use of these thiopurines during pregnancy is considered relatively 
safe.6,7,8,9,10
In contrast to MP and its precursor AZA, the metabolism 
of tioguanine [TG] is relatively simple, as TG is more directly 
converted to the pharmacologically active 6-thioguaninenucleo-
tides [6-TGN]. Tioguanine [TG] is considered a potential rescue 
thiopurine which has shown to be effective in case of intolerance 
or resistance to conventional thiopurines.11,12,13,14 An unfavour-
able ‘skewed’ thiopurine metabolism, in which predominantly 
6-methylmercaptopurine [6-MMP] is produced instead of the 
desired 6-TGN, is also considered a reason for alternative thio-
purine therapy.14 Since part of the generated end metabolites 
of TG, being 6-TGN, is the same as during AZA and MP ther-
apy, one could assume the same influence of TG on pregnancy 
outcomes.
Available data on the use of TG during pregnancy are scarce15 
and consists of only two patients with Crohn’s disease [CD] with no 
adverse pregnancy outcomes.16 Therefore, the aim of this study on 
female IBD patients was to describe the safety and teratogenicity of 
TG during pregnancy in a larger group of patients.
2. Materials and Methods
2.1. Study design
The VU University Medical Center [VUmc] IBD database was scruti-
nised for this retrospective study. The Initiative on Crohn and Colitis 
[ICC] and Nurses Initiative on Crohn and Colitis [NICC] network, 
being all university IBD centres in The Netherlands, were contacted 
as well, in search for additional cases, between 2003 and December 
2014. Female IBD patients were included if they were treated with 
TG at some point during pregnancy. The two patients described by 
de Boer in 2005 were also included.16
The primary goal of this study was to describe the number and 
aspect of birth defects, and in addition to portray the rate of miscar-
riage, preterm delivery [< 37 weeks], low birthweight, and neonatal 
morbidity. Secondary endpoints of this study were to describe com-
plications during pregnancy, method of delivery, course after delivery, 
signs of myelosuppression or hepatotoxicity in the neonate, thiopu-
rine metabolite measurements, and follow-up. Ethics approval was 
obtained from the medical ethics board of VU University Medical 
Center.
2.2. Demographic and IBD-related characteristics
At baseline, the following data on patient characteristics were col-
lected: type of IBD [CD, ulcerative colitis [UC], or IBD unclassified], 
localisation of IBD, duration of IBD at initiation of TG treatment 
and conception, medication history, and co-medication. Data on 
duration between diagnosis, TG treatment, and conception were 
collected in whole years. Patients were classified according to the 
Montreal classification.17
2.3. Pregnancy outcome and neonatal 
characteristics
The following data were collected on obstetric history, pregnancy, 
and neonatal outcome: previous pregnancies and outcome, sponta-
neous abortions, course of pregnancy, flare of disease activity dur-
ing pregnancy and treatment, fetal ultrasound abnormalities, mode 
of delivery, indications for operative delivery, gender, birthweight, 
gestational age at birth, congenital abnormalities, neonatal compli-
cations, and neonatal ward admission. Birthweight percentile cat-
egories were calculated according to gender and gestational age at 
birth.18
2.4. Laboratory tests
If measured, thiopurine metabolite 6-TGN concentrations in red 
blood cells [RBCs] were determined using the Dervieux method.19 
Existing literature generally utilises the Lennard method20 for deter-
mination of thiopurine metabolites. To compare our data, 6-TGN 
concentrations were re-calculated by dividing the concentrations by 
a converting factor of 2.6.21
In blood, both cord blood and neonatal venepuncture, poten-
tial toxicity [bone marrow depression and hepatotoxicity] due to 
maternal thiopurine use was analysed. In newborns, leukopenia 
was defined as a leucocyte count below 5*109/l, anaemia as a hae-
moglobin level below 10 mmol/l and thrombocytopenia as a plate-
let count below 150*109/l22. Hepatotoxicity was defined as either 
alanine aminotransferase [ALT] > 50 U/l, aspartate aminotrans-
ferase [AST] > 140 U/l, alkaline phosphatase [AP] > 300 U/l, or 
gamma glutamyltransferase][GGT] > 263 U/l.23 Hypoglycaemia 
was defined as blood glucose level below 3.0  mmol/l. Neonatal 
hyperbilirubinaemia was defined as bilirubin level at Day 1 above 
100 µmol/l.23
2.5. Data analysis
Demographic data are given descriptively and tabulated. Separate 
cases are noted as #[patient]/no.[neonate]. Data are expressed as 
median with interquartile range [IQR] according to distribution. 
Median birthweight and median gestational age at birth are deter-
mined for the singleton pregnancies. No further statistical analysis 
was performed, as the group of patients was too small for proper 
analysis. Outcomes were compared with data from a recent Dutch 
prospective cohort study on the use of conventional thiopurines in 
pregnant IBD patients.7
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A total of 13 female patients were included with a median age at diag-
nosis of 20 years old [IQR 17–22] from six hospitals. Crohn’s disease 
and UC were diagnosed in 10 [78%] and 3 [23%] patients, respec-
tively. Maternal characteristics are provided in Table 1.
Reasons for initiation of TG treatment include a combination 
of the following: corticosteroid dependency [N = 3], failure and/or 
intolerance of corticosteroid therapy [N = 3], failure and/or intoler-
ance using conventional thiopurines [N = 11], failure and/or intol-
erance on 5-aminosalicylic acid [5-ASA] treatment [N = 3], loss of 
response and/or intolerance of anti-tumour necrosis factor-α [anti-
TNF-α] [mono]therapy [N  =  4], negative effects of methotrexate 
[N = 2], or a ‘skewed’ thiopurine metabolism [N = 2].
Median duration of diagnosis to initiation of TG treatment was 
9 years [IQR 4–11]. Median dose of TG during pregnancy was 18 g/
day [IQR 18–21]; three patients were dosed three times a week 
instead of daily administration. All patients received TG through-
out the entire pregnancy, except for one [case #12/1] in whom TG 
therapy was terminated at 30 weeks of gestation. Co-medication was 
received in six patients, (anti-TNF-α [N = 2], 5-ASA [N = 2], and 
corticosteroids [N = 4]) .
3.2. Pregnancy characteristics
All 13 patients using TG during pregnancy, with a total of 19 preg-
nancies including one monochorionic twin pregnancy were included 
[Table 2]. In line with good clinical practice, patients received a pre-
counselling talk on the safety of TG treatment during pregnancy, 
using the scarce data.15 Median age at conception was 33 years [IQR 
27–36]. Median duration of initiation of TG treatment to concep-
tion was 2 years [IQR 12.5], median duration of diagnosis to con-
ception was 11 years [IQR 8–13]. Three patients became pregnant 
by in-vitro fertilization [IVF], including one patient [case #5] with 
polycystic ovary syndrome [PCOS] who had a spontaneous abortion 
in her first pregnancy and in her third pregnancy; after IVF, she car-
ried the monochorionic twins mentioned above.
3.3. Maternal complications during pregnancy
Two pregnancies [#1/1 and #5/2] were complicated by [mild] preg-
nancy-induced hypertension [PIH] for which no medical treatment 
was necessary. The twin pregnancy [#5/3 and #5/4] and one other 
pregnancy [#10/2] were complicated by pre-eclampsia. In three 
patients [#3, #8, and #10] a flare in IBD disease activity was treated 
with an induction tapering scheme of glucocorticoids. Other than 
in the three patients experiencing a flare, no IBD-related laboratory 
changes were observed during pregnancy.
3.4. Pregnancy outcomes
Three pregnancies resulted in a spontaneous abortion [16%] in the 
first trimester during TG treatment. All three patients had an ongoing 
pregnancy in the years following the miscarriage during TG therapy.
In 7 of the 16 ongoing pregnancies, delivery was by caesarean 
section. Four elective caesarean sections were performed, indicated 
by perianal disease [N = 3] and breech position of the fetus [N = 1]. 
Three emergency caesareans were performed because of obstructed 
labour in two, and for suspected fetal distress in the twin pregnancy. 
In this monochorionic twin pregnancy, labour was induced at 35 
+ 1 weeks of gestation because of pre-eclampsia [cases #5/3 and 
#5/4]. Due to suspected fetal distress during induction, an emer-
gency caesarean was performed. In total, 17 neonates were born. 
Of the 15 singleton newborns, median gestational age at birth was 
39 weeks [IQR 38–40] and median birthweight was 3410 g [IQR 
3267–3815]. The twins were born with birthweights of 2470 g and 
2160 g, respectively.
3.5. Neonatal complications
Admission to the neonatology unit was indicated in five new-
borns, of whom the characteristics are described in Table 3. The 
monochorionic twins were both admitted to the neonatology unit 
because of infant respiratory distress syndrome [IRDS] grade 2, 
treated with continuous positive airway pressure [CPAP], and 
postpartum transient hypotonia due to maternal labetalol use for 
pre-eclampsia.
Table 1. Patient characteristics. Values are number or median (interquartile range [IQR]). 
Patient characteristics [mothers] [N = 13] Jharap [2014] [N = 30]7
Age at diagnosis [years] 20 [17–22] 21
CD/UC 10/3 24/6
Montreal classification of UC patients
▪  E2 1 3
▪  E3 2 3
Montreal classification of CD patients
▪  A1/A2/A3 1/9/0 7/17/0
▪  L1/L2/L3 2/3/5 7/7/10
▪  B1/B2/B3/B1p/B2p/B3p/missing 5/3/1/0/0/1/0 11/4/0/7/1/0/1
Parity [≥ 1] 7 -
No. of patients with previous spontaneous abortion 2 -
No. of patients with previous IBD surgery 3 -
Age at conception [years] 33 [27–36] 30 [27–33]
Duration IBD to conception 11 [8–13] 8.5 [6–12]
Dose of TG [mg/day] 18 [18–21] -
Co-medication
▪  Anti-TNF-α 2 3
▪  5-ASA 2 6
▪  Corticosteroids 4 2
IBD, inflammatory bowel disease; 5-ASA, 5-aminosalicylic acid; CD, Crohn’s disease; TG, tioguanine; anti-TNF-α, anti-tumour necrosis factor-α; UC, ulcerative 
colitis.
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In one pregnancy [case #12/1] the fetus was in a breech pres-
entation. After birth by elective caesarean section, the neonate was 
admitted to the neonatology unit because of transient tachypnoea 
of the newborn [TTN] which indicated CPAP therapy. Also, a sacral 
dimple was found on physical examination, but ultrasonography 
showed no neural tube defect.
Two neonates [12%] were large for gestational age [LGA: birth-
weight percentile > 97.7]. Of these one [case #1/1] was admitted 
to the neonatal ward because of hypoglycaemia, which normalised 
after glucose infusions, and premature atrial contractions [PACs] 
which spontaneously resolved. In this neonate, a distal shaft hypo-
spadias was diagnosed by the paediatric urologist.
One neonate [case #5/2] was briefly admitted to the neonatal 
ward for glucose control and an adrenocorticotropic hormone 
[ACTH] test because of maternal prednisone use, with no adverse 
outcomes.
3.6. Laboratory testing
Five neonates were laboratory tested for myelosuppression in 
either cord blood or by neonatal thrombocytopenia. No anaemia, 
leukopenia, or thrombocytopenia was observed. No hepatotoxic-
ity was found in the three neonates checked. No clinically relevant 
maternal liver test abnormalities were observed during pregnancy. 
Hypoglycaemia was detected in 60% of the five newborns tested.
Umbilical cord 6-TGN concentrations were measured in four 
newborns. In three, the 6-TGN concentration was below detect-
able level; in one newborn, the re-calculated concentration was 38 
pmol/8*108 RBC.16
3.7. Comparison pregnancy cohort using 
conventional thiopurines
The population from a recent prospective cohort study in The 
Netherlands, on maternal conventional thiopurine therapy during 
pregnancy,7 closely resembles our TG cohort as based on the patient 
and disease characteristics [Table 1]. In addition, neonatal outcomes 
match with our rate of congenital abnormalities, birthweight ,and 
gestational age at birth [Table 4].
4. Discussion
Our descriptive study demonstrates that TG treatment in pregnant 
IBD patients appears to be relatively safe: 19 pregnancies in 13 
patients resulted in 17 neonates, including one with a mild congeni-
tal abnormality. Five newborns required [short-term] neonatal ward 
admission, including the twins after induced preterm labour. Low 
birthweight [< 2500 g] was only observed in these twins, and in none 
of the singletons.
Conventional thiopurine treatment during pregnancy in IBD 
patients is considered relatively safe. There is no association with an 
increase in the rate of congenital abnormalities or low birthweight 
when adjusted for disease activity, though it may increase the risk 
of preterm birth,6 neonatal anaemia, and leukopenia.7 Also, mater-
nal thiopurine treatment during pregnancy does not seem to affect 
the long-term development or immune function of children up to 
6  years of age.10 As the metabolites of TG are partially the same 
as the metabolites of AZA and MP, a comparable impact of TG on 
pregnancy outcomes could be expected.
Therefore we compared our patient data and outcomes with a 
Dutch age-matched IBD cohort of 30 women taking conventional 
thiopurines during pregnancy.7 As shown in Tables 1 and 4, not only 
the patient group but also the pregnancy outcomes, i.e. birthweight 
and rate of congenital abnormalities, are highly similar.
In our study, the observed birthweight was comparable to the 
normal ranges within the data from the 10-year prospective peri-
natal registration in The Netherlands.24 Low birthweight [LBW], 
specified as birthweight below 2500 g, occurred in our study only 
Table 3. Neonatal characteristics. Values are number [percentage] or median (interquartile range [IQR]).
Neonatal characteristics [N = 17] Jharap [2014] [N = 31]7
Congenital anomalies 1a [6%] 2b [6.5%]
Gestational age at birth [weeks] 39 [38–40] 39 [38–40.1]
▪  Preterm birth [< 37 wk GA] 2c [12%] 3 c [10%]
▪  Post-term birth [> 42 wk GA] 0 [0%] 0 [0%]
Birthweight [g] 3410 [3267–3815] 3410 [3200–3680]
▪  LBW [1500–2500 g] 2 c [12%] 3 c [10%]
▪  SGA [p < 10] 0 [0%] -
▪  LGA [p > 97.7] 2 [12%] -
Neonatal ward admission 5 c [29%] -
Anaemia 0/5 [0%] 10 [63%]
GA, gestational age; wk, weeks; LBW, low birthweight; LGA, large for gestational age; SGA, small for gestational age.
aDistal shaft hypospadias in patient #1/1 whose father also has a congenital hypospadias.
bClubfoot and isolated ptosis of left eye.
c Including the twins.
Table  2. Pregnancy characteristics. Values are absolute number 
[percentage]. 
Pregnancy characteristics [N = 19]
Spontaneous abortion 3a [16%]
Complicated pregnancy 6
▪  Flare IBD 3
▪  Pregnancy-induced hypertension 2
▪  Pre-eclampsia 2
Mode of delivery 16
▪  Elective caesarean section 4
▪  Emergency caesarean section 3b
▪  Vaginal delivery 9
IBD, inflammatory bowel disease.
aOne spontaneous abortion after in-vitro fertilisation in a patient with 
polycystic ovary syndrome. bIncluding one twin pregnancy.
162 S. A. van den Berg et al.
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in the twin pregnancy. No intrauterine growth restriction defined as 
birthweight percentile [p < 10], was observed.
A meta-analysis on the influence of IBD on pregnancy shows an 
increased rate of LBW in IBD patients compared with a non-IBD 
population.3 In the general Dutch population, the rate of LBW is 
6.9%.24 In our cohort, no LBW was observed in the singleton preg-
nancies, whereas a French study on pregnancy outcome in IBD 
patients treated with conventional thiopurines shows a LBW rate 
of 15.8%.8
Inflammatory bowel disease also influences the rate of prematu-
rity [< 37 weeks of gestation] compared with controls.3 In conven-
tional maternal thiopurine treatment, rates up to 36.2% of preterm 
birth are reported,8,9 compared with 7.7% as documented by the 
perinatal registration in The Netherlands.24 No preterm birth in sin-
gleton pregnancies was observed in our case series. Only the twin 
pregnancy resulted in an iatrogenic preterm birth.
One congenital abnormality was diagnosed, namely a distal shaft 
hypospadias in a neonate whose father also had congenital hypospa-
dias. The prevalence of congenital hypospadias in The Netherlands 
is 19.8 per 10.000 births.24 Studies on maternal thiopurine treatment 
in IBD report rates of 3.6–6.5%7,8,9 of congenital abnormalities, 
whereas the rate of congenital abnormalities in the general popula-
tion in The Netherlands is 2.7%.26 However, next to an increased 
rate of low birthweight and prematurity, the meta-analysis on the 
influence of IBD on pregnancy also shows a 2.37-fold increased risk 
of congenital abnormalities compared with a non-IBD population.3 
Moreover, hypospadias shows familial clustering,27 and environmen-
tal factors including maternal drug use during pregnancy are also 
contributing factors.28 Therefore, we cannot determine whether the 
congenital hypospadias in this case is a consequence of IBD disease 
activity or maternal therapy, or has a familial cause.
Three pregnancies [16%] ended in a spontaneous abortion in 
the first trimester. Several maternal risk factors were present, includ-
ing maternal age above 35 years, previous spontaneous abortions, 
comorbid PCOS and conception by IVF.29 Since our cohort is rela-
tively small, we believe no firm conclusions can be drawn from 
this rate.
In five newborns, a blood sample was drawn for analysis of 
potential toxicity [hepatotoxicity and myelosuppression] of mater-
nal thiopurine therapy. No anaemia was present, although another 
study observed a rate of 60% [in 31 newborns] of anaemia after 
intrauterine exposure to conventional thiopurines.7
We acknowledge several limitations in this retrospective study. 
Because of the design of the study, disease activity at conception and 
during pregnancy was not documented. Data on smoking and alco-
hol intake during pregnancy were not available in the outpatient 
gastroenterology medical reports. Dosage of medication was not re-
calculated to mg/kg since data on maternal weight were not retro-
spectively obtainable. We recognise the probable existence of missed 
and therefore unreported cases. Also, precise numbers on voluntarily 
childlessness using TG treatment are missing, though this finding is 
mentioned by several gastroenterologists contributing to this arti-
cle. Despite the multicentre design, the sample size was relatively 
small; however, our study represents the largest case series so far 
in literature. In the majority of neonates no [long-] follow-up was 
performed.
Our study reveals a lower incidence of adverse pregnancy out-
comes compared with the general Dutch population, though unfa-
vourable effects of IBD disease activity itself were expected.3 Low 
birthweight and preterm birth were not observed in the singleton 
pregnancies. This is a reassuring outcome, especially when compared 
with general data on IBD disease activity during pregnancy3 and 
evidence on conventional maternal thiopurine therapy during preg-
nancy,6,7 which show increased rates of both LBW and preterm birth. 
Only the twin pregnancy resulted in neonates with LBW after a pre-
term delivery, which is an average pregnancy outcome for twins. 
Also, the one [mild] congenital abnormality in this cohort has multi-
factorial potential causes.3,27,28
In conclusion, this relatively small case series shows promising 
outcomes and supports safe use of TG in pregnant IBD patients. 
Although there is no evident proof of teratogenicity, consideration 
should be given to the indication and continuation of TG during 
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